Mirum Pharmaceuticals, Inc. research snapshot
MIRM AI stock analysis currently reads Mirum Pharmaceuticals as a commercial-stage rare liver disease biotech with three approved medicines, rapidly growing revenue, high gross margins, and a deep pipeline. At the July 10, 2026 data cutoff, the quoted price was $122.13, market capitalization was about $7.45 billion, and the stock was trading near its 52-week high. All 13 covering analysts rate it a Buy with an average target of $147. The analysis uses a scenario framework, not a price prediction. This page is informational research and not investment advice.
Current price
$122.13
Market cap
$7.45 billion
AI score
60 / 100
Rating
Commercial-stage rare disease biotech with growing revenue and high pipeline optionality
Trend status
Near 52-week high with constructive long-term trend
Data cutoff (updated weekly)
July 10, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Mirum sells approved rare liver disease medicines with high gross margins and growing revenue, but is still operating at a GAAP loss after a large Q1 2026 unusual charge. | Medium |
| Moat | The moat comes from approved rare disease drugs, regulatory exclusivity, specialized manufacturing, physician relationships, and pipeline depth in cholestatic liver disease, but can be challenged by competitors or new mechanisms. | Medium |
| Management | Management has built a commercial organization and advanced multiple pipeline programs. CEO Christopher Peetz sold $2.4 million in stock in July 2026, which warrants monitoring for insider conviction. | Medium |
| Financial trend | Revenue has grown steadily from $128M (Jun 2025 quarter) to $160M (Mar 2026 quarter), with gross margins around 81%. TTM net income of -$799M included a large unusual charge; adjusted operations show a narrower loss. | Medium-high |
| Valuation | At $122.13, P/S is about 13x TTM revenue of $570M. P/E is not useful while GAAP EPS is negative. Valuation depends on revenue growth duration, pipeline success probability, and path to profitability. | Medium |
| Technical trend | Price was near its 52-week high of $130 from a low of $50.25, suggesting a strong uptrend. Use live moving averages, support, resistance, and volume data before acting, and note the recent -4.36% daily drop as a caution signal. | Medium |
| Risk level | Risk includes the Q1 2026 large unusual charge, pipeline trial outcomes, regulatory decisions, commercial competition for Livmarli, insider selling, and the gap to sustainable GAAP profitability. | Medium-high |
| AI confidence | High for market data, revenue, and analyst consensus. Lower for the unusual charge explanation and pipeline probability weighting because detailed earnings call context was not fully accessible from public sources. | Medium |
| Investment certainty | Investment certainty is medium. MIRM has approved products and growing revenue, making it less speculative than pre-revenue biotechs, but GAAP losses, insider selling, and biotech event risk limit high-conviction conclusions. | Medium |
MIRM AI stock forecast
The MIRM AI stock forecast uses scenario ranges built from reported analyst targets and operational trends, not a P/E model, because GAAP EPS is negative. The forced P/E tool run for negative-EPS stocks produces unrealistic output, so the practical forecast relies on revenue growth trajectory, pipeline catalysts, and peer biotech valuation multiples.
$160 to $185
More likely if revenue growth continues above 20%, pipeline advances generate positive data, the company resolves the unusual charge context and demonstrates a clear path to GAAP profitability, and the stock re-rates toward the analyst high target of $185.
$135 to $155
More likely if revenue grows at 15-20% annually, pipeline data is mixed but not negative, operating losses narrow steadily, and the stock trades around the consensus analyst target of $147 with normal biotech volatility.
$90 to $125
More likely if revenue growth slows, pipeline trials disappoint, the unusual charge signals deeper financial issues, competition emerges for Livmarli, or insider selling accelerates, and technical support near the 52-week low area is tested.
MIRM AI technical analysis
MIRM AI technical analysis starts from the $122.13 quote and the observed trading activity. The stock was near its 52-week high of $130.00, with a 52-week low of $50.25, implying a strong uptrend over the past year. The recent -4.36% daily move and below-average volume of 539K (vs 976K average) suggest a pause in momentum over the data cutoff. Live chart confirmation is needed before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $122.13 | Current quote used for this page as of the July 10, 2026 data cutoff. After-hours at $122.50. |
| Near support | $112.36 to $118.54 | Estimated from the recent daily low of $118.54 and prior trading range. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $127.51 to $130.00 | Estimated from the daily high of $127.51 and the 52-week high of $130.00. A close above this zone would signal continued momentum. |
| 50-day moving average | Requires live chart confirmation | Use current chart data before acting. The page does not fetch request-time market data. |
| 200-day moving average | Requires live chart confirmation | Long-term trend confirmation should be checked against a live chart or broker data. |
| Momentum | Near 52-week high with recent pullback | The stock has rallied significantly from $50.25 to $130 but the recent -4.36% daily drop and below-average volume suggest a potential pause or consolidation. |
| Volume | 539,125 (below 975,810 average) | Below-average volume on the pullback day suggests the sell-off may lack strong conviction, but also limits confirmation signals. |
| Volatility | Moderate for biotech | Beta of 0.48 suggests lower volatility than the broad market, but biotech event risk can cause sudden moves. |
| Invalidation | Close below $112.36 | A decisive close below the support zone would weaken the short-term bullish setup. |
MIRM AI trading strategy
The MIRM AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh filings, pipeline news, or earnings checks.
Wait for MIRM to reclaim above $127.51 with volume above the 976K average, confirming that the pullback was a pause and buyers are returning.
A close below the $112.36 support zone or earnings with disappointing revenue guidance should invalidate the setup.
If MIRM pulls back into the $112.36 to $118.54 support band without a fundamental thesis break, compare price action with the next quarterly filing, pipeline updates, and insider trading activity.
Do not average down without a predefined maximum loss and a review of whether the Q1 2026 unusual charge signals a structural issue.
Track the evidence that matters most for Mirum: Livmarli revenue growth, pipeline advancement, operating expense trends, cash position, the path to GAAP profitability, and insider buying or selling patterns.
Reduce confidence when price moves are driven solely by analyst upgrades without matching revenue or pipeline evidence.
Investment research summary
Mirum develops and commercializes medicines for rare liver diseases. Its approved product Livmarli treats cholestatic pruritus in Alagille syndrome and PFIC, generating rapidly growing revenue with high gross margins.
The moat comes from approved rare disease therapies, regulatory exclusivity periods, specialized manufacturing and distribution, deep physician relationships in hepatology, and a pipeline targeting additional cholestatic liver conditions.
The thesis can fail if Livmarli faces new competition, pipeline trials miss endpoints, the Q1 2026 unusual charge signals deeper financial issues, the company fails to reach profitability before cash concerns arise, or key management departure follows insider stock sales.
Management has advanced from a development-stage company to a commercial organization with three approved products and a pipeline partnership with Incyte. CEO Christopher Peetz sold $2.4 million in stock in July 2026, which needs monitoring for conviction signals.
Rare liver disease treatment is a growing specialty with high unmet need, regulatory incentives (orphan drug status, priority review), and strong pricing power for approved therapies. However, clinical development remains high-risk and capital-intensive.
At $122.13, MIRM trades at about 13x TTM revenue with negative GAAP EPS. The valuation implies confidence in continued revenue growth and pipeline progress. Margin of safety is thin if revenue growth decelerates or the path to profitability extends significantly.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MIRM price | $122.13 | Google Finance quote snapshot | July 10, 2026 |
| Market capitalization | $7.45 billion, verified as $122.13 x 60.98M shares | financial_rigor.py market cap verification | July 10, 2026 |
| Shares outstanding | 60.98 million | Google Finance | July 10, 2026 |
| TTM revenue (trailing 4 quarters) | $569.60 million | Google Finance quarterly income statement | July 10, 2026 |
| Gross margin (TTM) | Approximately 81.4% | Calculated from Google Finance quarterly income statement data | July 10, 2026 |
| TTM GAAP net income | -$798.85 million (includes ~$725M unusual charge in Q1 2026) | Google Finance quarterly income statement | July 10, 2026 |
| EPS (TTM) | -$13.60 | Google Finance | July 10, 2026 |
| 52-week range | $50.25 - $130.00 | Google Finance | July 10, 2026 |
| Analyst consensus | 13 Buy, 0 Hold, 0 Sell. Avg target $147, range $125-$185 | Google Finance analyst ratings | July 10, 2026 |
| Financial statement depth | SEC filings available. Two-source detailed balance sheet and cash flow checks still needed for in-depth investment use. | Research quality note | July 10, 2026 |
This MIRM AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of July 10, 2026, may be incomplete, and can be wrong if new filings, pipeline data, FDA decisions, market prices, company events, or macro conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
